Neel Gandhi, M.D., is a physician-scientist at Emory's Rollins School of Public Health with 80% effort dedicated to patient-oriented research (POR). He seeks funding through the K24 Midcareer Investigator Award to expand his POR program in drug-resistant tuberculosis (TB), HIV and global health, and to mentor clinical investigators in these areas. The intersection between drug-resistant TB and HIV is an emerging global public health issue which threatens a decade of gains in TB control. There is a growing need for innovative research in TB genomics, immunology, and therapeutics, in addition to developing a pool of scientists trained in TB/HIV and global health POR. Dr. Gandhi has demonstrated a commitment to clinical, epidemiologic and translational research in TB/HIV and global health over the past decade, including a strong record of successfully mentoring 24 trainees, to date. Emory University provides a robust environment for training clinical investigators through its degree programs (MPH, MS, PhD), post-doctoral fellowships and multi-disciplinary centers (CTSA, CFAR, Global Health). Within this highly conducive training environment, Dr. Gandhi has created a comprehensive mentoring program that focuses on the design and responsible conduct of hypothesis-driven research to assist trainees in becoming independent investigators. This K24 award will greatly facilitate the PI's immediate and long-term career goals, which include to: 1) Understand how whole genome sequencing can further elucidate mechanisms of acquired resistance and transmission in drug- resistant TB epidemics;2) Advance his knowledge of human immunology to inform future studies of increased TB susceptibility among HIV-infected individuals;3) Expand clinical trials skills to facilitate the design and implementation of drug-resistant TB and TB/HIV trials;and 4) Enhance the structure and content of his mentorship of trainees pursuing careers in patient- oriented TB, HIV and Global Health research. This award will utilize a framework of multiple NIH-funded studies in drug-resistant TB and HIV in South Africa to investigate two novel specific research aims: 1) To examine polymorphisms in the M.tuberculosis genome which arise among MDR TB subjects who develop additional resistance on treatment, and 2) To investigate the incremental yield of whole genome sequencing in identifying micro-clusters of XDR TB transmission in large genotypic clusters. The K24 award will allow Dr. Gandhi to continue his highly-successful research program in TB, HIV and global health, and mentor the next generation of investigators in this vital research field.

Public Health Relevance

The intersection between drug-resistant TB and HIV is a growing global public health issue which threatens a decade of gains in TB control. Neel Gandhi, M.D., is a physician-scientist at Emory's Rollins School of Public Health dedicated to patient-oriented research in TB, HIV and global health. The K24 award will provide the needed protected time for Dr. Gandhi to provide mentorship to young investigators pursuing these fields and to expand his research program in the emerging areas of TB genomics, immunology and clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
1K24AI114444-01
Application #
8790305
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Program Officer
Srinivasan, Sudha
Project Start
2014-06-01
Project End
2019-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
1
Fiscal Year
2014
Total Cost
$173,842
Indirect Cost
$12,877
Name
Emory University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Buchacz, Kate; Lau, Bryan; Jing, Yuezhou et al. (2016) Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis 214:862-72
Auld, Sara C; Lee, Scott H; Click, Eleanor S et al. (2016) Interferon Gamma Release Assay Result is Associated with Disease Site and Death in Active Tuberculosis. Ann Am Thorac Soc :
Salindri, Argita D; Kipiani, Maia; Kempker, Russell R et al. (2016) Diabetes Reduces the Rate of Sputum Culture Conversion in Patients With Newly Diagnosed Multidrug-Resistant Tuberculosis. Open Forum Infect Dis 3:ofw126
Magee, M J; Foote, M; Ray, S M et al. (2016) Diabetes mellitus and extrapulmonary tuberculosis: site distribution and risk of mortality. Epidemiol Infect 144:2209-16
Edelman, E J; Tate, J P; Fiellin, D A et al. (2015) Impact of defined clinical population and missing data on temporal trends in HIV viral load estimation within a health care system. HIV Med 16:346-54
Magee, M J; Kempker, R R; Kipiani, M et al. (2015) Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia. Int J Tuberc Lung Dis 19:685-92
Interrante, Julia D; Haddad, Maryam B; Kim, Lindsay et al. (2015) Reply: Missing Stowaways and Lack of Expected Concurrent Infections. Ann Am Thorac Soc 12:1898-9
Lodi, Sara; Phillips, Andrew; Logan, Roger et al. (2015) Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV 2:e335-43
Lim, Jennifer R; Gandhi, Neel R; Mthiyane, Thuli et al. (2015) Incidence and Geographic Distribution of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa. PLoS One 10:e0132076
Viswanathan, Shilpa; Justice, Amy C; Alexander, G Caleb et al. (2015) Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr 69:493-8

Showing the most recent 10 out of 12 publications